切换至 "中华医学电子期刊资源库"

中华结直肠疾病电子杂志 ›› 2020, Vol. 09 ›› Issue (04) : 349 -354. doi: 10.3877/cma.j.issn.2095-3224.2020.04.005

所属专题: 文献

论著

雷替曲塞联合伊立替康治疗晚期结直肠癌的临床观察
马玉洁1, 陈冬娜1, 梁向伟1, 孙永琨2,()   
  1. 1. 100122 北京市朝阳区三环肿瘤医院内科
    2. 100021 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院内科
  • 收稿日期:2020-04-14 出版日期:2020-08-25
  • 通信作者: 孙永琨

Clinical observation on raltitrexed combind with irinotecan in the treatment of advanced colorectal cancer patients

Yujie Ma1, Dongna Chen1, Xiangwei Liang1, Yongkun Sun2,()   

  1. 1. Sanhuan Cancer Hospital, Chaoyang District, Beijing 100122, China
    2. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100021, China
  • Received:2020-04-14 Published:2020-08-25
  • Corresponding author: Yongkun Sun
  • About author:
    Corresponding author: Sun Yongkun, Email:
引用本文:

马玉洁, 陈冬娜, 梁向伟, 孙永琨. 雷替曲塞联合伊立替康治疗晚期结直肠癌的临床观察[J/OL]. 中华结直肠疾病电子杂志, 2020, 09(04): 349-354.

Yujie Ma, Dongna Chen, Xiangwei Liang, Yongkun Sun. Clinical observation on raltitrexed combind with irinotecan in the treatment of advanced colorectal cancer patients[J/OL]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2020, 09(04): 349-354.

目的

分析雷替曲塞联合伊立替康治疗晚期结直肠癌的疗效及安全性。

方法

纳入中国医学科学院肿瘤医院内科2015年1月至2018年12月收治的34例既往一线或二线使用含氟尿嘧啶类化疗方案失败的晚期结直肠癌患者,接受雷替曲塞联合伊立替康方案治疗,主要观察终点为客观有效率(ORR),次要观察终点包括疾病无进展生存时间(PFS)、总生存时间(OS)、疾病控制率(DCR)和安全性。

结果

34例患者病理确诊均为结直肠腺癌。近期疗效中观察到部分缓解(PR)为6例,疾病稳定(SD)为25例,疾病进展(PD)为3例,客观有效率(ORR)为17.6%(6/34),疾病控制率(DCR)为91.2%(31/34)。其中,二线患者ORR为21.7%(5/23),DCR为91.3%(21/23);三线患者ORR为9.1%(1/11),DCR为90.9%(10/11)。34位患者全部追踪至疾病进展,疾病无进展中位生存时间(mPFS)为180天(95% CI:157.2~202.8),截止2020年2月27日末次随访未观察到中位总生存时间(mOS),平均OS(389.0±51.1)天。其中,接受二线治疗患者的mPFS为193天,平均OS(412.0±61.5)天。接受三线治疗患者的mPFS为150天,mOS为311天。治疗后肿瘤标志物CEA与CA19-9水平均有降低,其中CA19-9治疗前后平均水平为(169.8±48.0)U/mL和(143.8±57.7)U/mL(t=0.700,P=0.655)。CEA治疗前平均水平为(255.0±40.6)ng/mL,治疗后为(104.2±32.4)ng/mL,下降趋势经比较差异具有统计学意义(t=1.759,P=0.001)。安全性方面,常见不良反应包括恶心呕吐、腹泻、白细胞及中性粒细胞减少、血红蛋白降低和转氨酶升高等,多为Ⅰ~Ⅱ级,Ⅲ级不良反应有中性粒细胞减少(2/34)、白细胞减少(1/34)和转氨酶升高(1/34),无Ⅳ级不良反应及化疗相关死亡事件发生。

结论

雷替曲塞联合伊立替康治疗晚期结直肠癌疗效确切,安全性良好。其中二线治疗ORR与国内外既往研究相似,但不良反应更低,值得临床进一步推广应用。

Objective

To evaluate the efficacy and safety of raltitrexed combind with irinotecan in patients with metastatic colorectal cancer (mCRC).

Methods

Between January 2015 and December 2018, a total of 34 patients with mCRC after the failure of first-line or second-line chemotherapy were selected and treated with raltitrexed plus irinotecan in Cancer Hospital Chinese Academy of Medical Sciences. The primary endpoint was objective response rate (ORR), and the secondary endpoints were disease control rate (DCR), progress-free survival (PFS), overall survival (OS) and safety.

Results

The pathology of 34 patients was adenocarcinoma. There were 16 patients (47.1%) with rectal cancer, followed by 10 cases (29.4%) in the left colon and 8 cases (23.5%) in the right colon. Thirty patients (88.2%) accepted undergone surgical treatment. Six achieved a partial response (PR), Twenty-five had a stable disease (SD) and 3 had a progressive disease (PD). The ORR was 17.6% (6/34), and the DCR was 91.2% (31/34). For second-line treatment, the ORR was 21.7% (5/23), DCR was 91.3% (21/23). For third-line treatment, the ORR was 9.1% (1/11), DCR was 90.9% (10/11). All patients were defined progression of disease, the median progression free survival (mPFS) was 180 days(95% CI: 157.2~202.8). The median overall survival (mOS) was not observed at the last follow-up. The average OS was (389±51.1)days. the median PFS of patients receiving second-line treatment was 193 days, with an average OS of (412±61.5)days. Patients receiving third-line treatment had mPFS of 150 days and mOS of 311 days. The levels of tumor markers CEA and CA19-9 decreased after treatment. The average levels of CA19-9 before and after treatment were 169.8±48.0 U/mL and 143.8±57.7 U/mL (t=0.700, P=0.655). The average level of CEA before treatment was (255.0±40.6) ng/mL and (104.2±32.4) ng/mL after treatment, the decline has statistically significant (t=1.759, P=0.001). The main adverse reactions were nausea, vomiting, diarrhea, leucopenia, neutropenia, hemoglobin reduction and transaminase elevation, mostly grade I or II. Grade III adverse reactions included leucopenia (2/34), anemia (1/34) and transaminase elevation (1/34). There were no grade IV adverse reactions and treatment-related deaths.

Conclusion

The combination of raltitrexed combined with irinotecanas second-line and above treatment could be an efficient and safe option for patients with mCRC. Particularly, it has presented encouraging ORR and lower toxicities as second-line therapy, which is worthy of further clinical application.

表1 患者基线特征[例(%)]
图1 无进展生存曲线
表1 临床疗效分析
表3 不良反应[例(%)]
[1]
郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41(1): 19-28.
[2]
纪丕军, 白威, 杨迁妮. 雷替曲塞单药方案三线治疗晚期结直肠癌的疗效观察[J].山西医药杂志, 2016, 45(13): 1567-1569.
[3]
王鹏, 何慧明. 雷替曲塞联合奥沙利铂治疗晚期结直肠癌疗效及对生活质量的影响[J].山西医药杂志, 2017, 46(24): 3044-3046.
[4]
蒋沁娟. 雷替曲塞、5-FU分别联合伊立替康治疗晚期结肠癌的效果比较[J].实用临床医药杂志, 2016, 20(17): 158-159.
[5]
TakiiY, YamazakiT, OkadaT, et al. Phase I/II trial of irinotecan and S-1 combination chemotherapy as a second-line treatment for advanced colorectal cancer[J]. Chemotherapy, 2013, 59(5): 338-343.
[6]
周建红, 李桂生, 李高峰, 等. 伊立替康联合雷替曲塞在晚期结直肠癌二线化疗中的疗效及安全性研究[J]. 中国全科医学, 2013, 16(5): 555-557.
[7]
Cunningham D, Zalcberg JR, Rath U, et al. FIinal results of a randomized trial comparing 'Tomudex'(raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group[J]. Ann Oncol, 1996, 7(9): 961-965.
[8]
Cocconi G, Cunningham D, Van Cutsem E, et al. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus highdose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group[J]. J Clin Oncol, 1998, 16(9): 2943-2452.
[9]
Cunningham D. Mature results from three large controlled studies with raltitrexed ('Tomudex')[J]. Br J Cancer, 1998, 77(supp12): 15-21.
[10]
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2): 228-247.
[11]
Chen AP, Setser A, Anadkat MJ, et al. Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0[J]. J Am Acad Dermatol, 2012, 67(5): 1025-1039.
[12]
Aschele C, Baldo C, Sobrero AF, et al. Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro[J]. Clin Cancer Res, 1998, 4(5): 1323-1330.
[13]
Aparicio J, Vicent JM, Maestu I, et al. Multicenter phase II trial evaluating a three-weekly schedule of irinotec an plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer[J]. Ann Oncol, 2003, 14(7): 1121-1125.
[14]
Vandendriessche B, Geurs F, HildersonI. Raltitrexed+irinotecan as second-line chemotherapy in elderly patients with advanced colorectal cancer[J]. Modern Chemotherapy, 2012, 1(2): 5-10.
[15]
Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer[J]. N Engl J Med, 2000, 343(13): 905-914.
[16]
Xu RH, Muro K, Morita S, et al. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial[J]. Lancet Oncol, 2018, 19(5): 660-671.
[17]
Polk A, Vaage-Nilsen M, Vistisen K, et al. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors[J]. Cancer Treat Rev, 2013, 39(8): 974-984.
[18]
Peng J, Dong C, Wang C, et al. Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study[J]. Cancer Commun (Lond), 2018, 38(1): 22.
[19]
Ransom D, Wilson K, Fournier M, et al. Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines[J]. Ann Oncol, 2014, 25(1): 117-121.
[1] 罗青杉, 梅海涛, 郝家领, 蔡锦锋, 周润楷, 温玉刚. 连接蛋白43通过调控细胞周期抑制结直肠癌的增殖机制研究[J/OL]. 中华普通外科学文献(电子版), 2024, 18(05): 344-349.
[2] 徐逸男. 不同术式治疗梗阻性左半结直肠癌的疗效观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 72-75.
[3] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[4] 梁轩豪, 李小荣, 李亮, 林昌伟. 肠梗阻支架置入术联合新辅助化疗治疗结直肠癌急性肠梗阻的疗效及其预后的Meta 分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 472-482.
[5] 严虹霞, 王晓娟, 张毅勋. 2 型糖尿病对结直肠癌患者肿瘤标记物、临床病理及预后的影响[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 483-487.
[6] 赵磊, 刘文志, 林峰, 于剑, 孙铭骏, 崔佑刚, 张旭, 衣宇鹏, 于宝胜, 冯宁. 深部热疗在改善结直肠癌术后辅助化疗副反应及生活质量中的作用研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 488-493.
[7] 黄海洋, 邝永龙, 陈嘉胜. 基层医院结直肠肿瘤经自然腔道取标本手术30 例分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 510-518.
[8] 任佳琪, 刁德昌, 何自衍, 张雪阳, 唐新, 李文娟, 李洪明, 卢新泉, 易小江. 网膜融合线导向的脾曲游离技术在左半结肠癌根治术中的应用[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 362-367.
[9] 张迪, 王春霞, 张学东, 李发馨, 庞淅文, 陈一锋, 张维胜, 王涛. 梗阻性左半结直肠癌自膨式金属支架置入后行腹腔镜手术与开腹手术的短期临床疗效比较[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 375-380.
[10] 张蔚林, 王哲学, 白峻阁, 黄忠诚, 肖志刚. 利用TCGA数据库构建基于miRNA的结直肠癌列线图预后模型[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 381-388.
[11] 张伟伟, 陈启, 翁和语, 黄亮. 随机森林模型预测T1 期结直肠癌淋巴结转移的初步研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 389-393.
[12] 季鹏程, 鄂一民, 陆晨, 喻春钊. 循环外泌体相关生物标志物在结直肠癌诊断中的研究进展[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(04): 265-273.
[13] 李佳莹, 王旭丹, 梁雪, 张雷, 李佳英. 1990~2021年中国结直肠癌死亡趋势分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(04): 274-279.
[14] 戈伟, 陈刚. 纳米炭导航行淋巴示踪在结直肠癌TNM分期中淋巴分期价值的临床研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(04): 288-293.
[15] 崔精, 鲍一帆, 沈晓明, 杨增辉, 高森, 鲍传庆. 结直肠癌中circMFSD12对肿瘤细胞功能及5-FU敏感性的调控[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(04): 294-302.
阅读次数
全文


摘要